

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 12, 2005

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-12957

2-2372868

(State or other jurisdiction (Commission file Number) (IRS Identification No.)
of incorporation)

685 Route 202/206, Bridgewater, New Jersey

08807

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (908) 541-8600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On May 12, 2005 Enzon Pharmaceuticals, Inc. appointed Robert C. Salisbury to Enzon's Board of Directors and Audit Committee. Enzon's Board of Directors has also determined that Mr. Salisbury is an "audit committee financial expert," as defined by the rules of the Securities Exchange Act of 1934. On May 16, 2005,

Enzon issued a press release announcing the appointment, which is attached to this current report as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No.	Description
99.1	Press Release dated May 16, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 16, 2005

By: /s/ Craig A. Tooman

Craig A. Tooman
Executive Vice President,
Strategic Planning
and Corporate Communications

Enzon Announces the Appointment of New Member to Its Board Of Directors

BRIDGEWATER, N.J.--(BUSINESS WIRE)--May 16, 2005--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Robert C. Salisbury has been appointed to the Company's Board of Directors and Audit Committee. Enzon's Board of Directors has also determined that Mr. Salisbury is an "audit committee financial expert," as defined by the rules of the Securities Exchange Act of 1934.

In 1998, Mr. Salisbury retired from Pharmacia & Upjohn, Inc. where he most recently served as Executive Vice President and Chief Financial Officer. In this capacity, Mr. Salisbury was responsible for all of the company's financial functions, as well as corporate strategy, human resources, investor relations, and corporate communications. Previously, Mr. Salisbury served as Executive Vice President, Finance and Chief Financial Officer at The Upjohn Company, where he played an integral role in planning, implementing, and integrating the merger between Pharmacia and The Upjohn Company in 1995. Mr. Salisbury first joined The Upjohn Company in 1974 and over a 20-year career, he served in various management posts in finance and strategic planning.

"Mr. Salisbury is a distinguished financial executive with more than 20 years of senior management experience in the pharmaceutical industry," said Jeffrey H. Buchalter, Enzon's chairman and chief executive officer. "Bob's extensive financial expertise will be a significant asset to our Board of Directors, as well as our audit committee."

Mr. Salisbury also serves as a director of the biotechnology company, Viragen, Inc. He received his Master of Business Administration in 1972 and his Bachelor of Science in finance in 1965 from Florida State University.

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Further information about Enzon can be found on the Company's web site at www.enzon.com.

All information in this press release is as of May 16, 2005 and the Company undertakes no duty to update this information.

CONTACT: Enzon Pharmaceuticals, Inc.
Susan Mesco
Director, Investor Relations
908-541-8678